Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04839601 · ClinicalTrials.gov registry record · NA
RNS System RESPONSE Study
A NA study, sponsored by NeuroPace.
- Terminated
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT04839601: Clinical Trial NA study, sponsored by NeuroPace.
NCT04839601 is a NA study that was terminated before completion, run by NeuroPace. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04839601, a NA study, was terminated before completion, sponsored by NeuroPace.
- TERMINATED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
Primary Outcome
The primary safety endpoint is the percent of subjects with serious device-related adverse events at 84 days (12 weeks) post-implant.
Interventions
- DEVICE RNS System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2025-05-01 |
| Phase | NA |
Why NCT04839601 stopped before completion
NCT04839601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which RNS System is the first listed.
NCT04839601 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04839601 about?
NCT04839601 is a clinical study titled "RNS System RESPONSE Study". To demonstrate that the RNS System is safe and effective as an adjunctive therapy in individuals age 12 through 17 years with medically refractory partial onset epilepsy.
What is the current status of trial NCT04839601?
This trial is currently terminated. It is a NA study. The enrollment target is 9 participants. The study started on 2021-10-27. Estimated completion is 2025-05-01.
What interventions are being tested in trial NCT04839601?
The interventions under investigation include: RNS System (DEVICE).
Who is sponsoring clinical trial NCT04839601?
This trial is sponsored by NeuroPace, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04839601's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI